NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development...
Pace of Jurisdictional Allowances Parallels Pre-Clinical and Regulatory ProgressHINGHAM, Mass., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq:...
TRV045 data reflected reduced seizure burden in nonclinical models of acute epilepsy presented at American College of Neuropsychopharmacology (ACNP) Annual...
Designation based on Akero’s Phase 2b HARMONY study finding that both the 50mg and 28mg EFX doses achieved statistical significance...
Independent Study Shows Moderate Dose Strength of XORLO™ Attenuates Kidney ExpansionCALGARY, Alberta, Dec. 08, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics...
BOSTON, MASSACHUSETTS, Dec. 08, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral...
Discontinuing unmodified TIL programs, including DELTA-1 and DELTA-2 trials of ITIL-168Prioritizing CoStAR-TIL programs for clinical development, including ITIL-306 in Phase...
Phase 2 clinical trial initiation expected in 2023Company to host conference call to discuss recent clinical updates, including updated data...
PHILADELPHIA, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company...
Announced positive top-line data for RAPIDe-1, a global Phase 2 study of PHVS416 for the on-demand treatment of HAE attacksParticipated...
Primary endpoint met, substantially reducing HAE attack symptomsAll secondary endpoints metPHVS416 was well tolerated at all dose levelsPharvaris to host...
Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4 Phase 1 trial enrolled all comers, with vast...
Data Presented at ESMO Immuno-Oncology CongressSOUTH SAN FRANCISCO, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT),...
Shineco, Inc. Stool test sample collectorBEIJING, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Shineco, Inc.(“Shineco” or the “Company”; NASDAQ: SISI), a...
SOLANA BEACH, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily...
POTOMAC, Md., Dec. 07, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- India Globalization Capital, Inc (NYSE American: IGC) (“IGC” or...
Newly issued patent expires in 2040BRIDGEWATER, N.J., Dec. 07, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or...
VANCOUVER, British Columbia, Dec. 07, 2022 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB :...
Program-Related Investment and Grant from the Bill & Melinda Gates Foundation to advance RIGImmune’s RNA therapeutics platform for influenza and...
Allowed Claims for Novel Immunotherapeutic Compound Constructed with Tissue Factor as Platform for Target Binding Domains Patent for Underlying Intellectual Property...